Aproveito e transcrevo um post hoje publicado por um analista do realmoney:
Adam Feuerstein
Abgenix
10/16/03 08:58 AM ET
"I guess Abgenix's (ABGX-Nasdaq) business development people have been busier than their clinical researchers – the biotech firm announced this morning a $100 million strategic alliance with AstraZeneca (AZN-NYSE) to discover and develop new cancer drugs.
For its $100 million, up-front equity investment in Abgenix, AstraZeneca gets commercial rights to 36 potential cancer targets, all of which are currently in preclinical development. Abgenix will conduct the early testing on these drugs and will manufacture them; AstraZeneca will then take over late-stage testing. If any of the drugs are successful and approved, Abgenix will receive royalty payments.
I've certainly been critical of Abgenix, most recently yesterday!, but this is a good development deal for them, no doubt about it. (Not that this impacts what I said yesterday, at all.) Now, let's just see how many real cancer drugs result from it."
(in
www.realmoney.com)